Physician

Shabana J Dewani, MD

According to 2025 Medicare claims, Shabana Dewani, MD (NPI: 1306928817) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is COLUMBUS ONCOLOGY ASSOCIATES INC (NPI: 1790875656; TIN: 311211874) and primary practice location at 43214-4359. Dewani is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Dewani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 349 traditional Medicare patients, billed 107,356 HCPCS/CPT codes, and received $1,676,318 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,095 prescription claims across 228 beneficiaries totaling $1,736,412 in drug costs, led by Kisqali (Ribociclib Succinate). DME data shows 15 claims. Open Payments data shows 2 records totaling $3,837. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $24,347 to $1,676,318. In contrast, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $1,242,132 to $1,736,412. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	177	401	$24,347
2016	259	652	$38,965
2017	285	40,806	$356,814
2018	267	78,879	$1,031,598
2019	274	94,358	$1,653,821
2020	257	80,062	$1,227,458
2021	328	64,272	$1,103,370
2022	360	114,459	$1,514,432
2023	343	110,644	$1,591,782
2024	349	107,356	$1,676,318

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	100	598	$1,242,132
2016	132	725	$1,772,644
2017	128	463	$787,017
2018	148	659	$351,249
2019	149	756	$541,942
2020	155	738	$684,251
2021	188	797	$723,075
2022	187	793	$408,720
2023	199	839	$788,630
2024	228	1,095	$1,736,412

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$704
2016	N/R	79	$31,564
2017	N/R	18	$14,329
2018	N/R	56	$1,323
2019	N/R	12	$226
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	26	$7,493
2024	N/R	15	$639

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	60	147	$130
96413	Administration of chemotherapy into vein, 1 hour or less	56	318	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	149	375	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	127	169	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	189	292	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kisqali	Ribociclib Succinate	24	672	$418,506
Verzenio	Abemaciclib	18	504	$263,132
Inlyta	Axitinib	11	330	$227,141
Brukinsa	Zanubrutinib	12	360	$184,408
Imbruvica	Ibrutinib	12	360	$133,975

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$639

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$3,837	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shabana J. Dewani, MD?

Tedicare shows public-source Medicare data for Shabana J. Dewani, MD (NPI 1306928817), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shabana J. Dewani, MD have ACO affiliation data?

Shabana J. Dewani, MD is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Shabana J. Dewani, MD?

Shabana J. Dewani, MD is linked to COLUMBUS ONCOLOGY ASSOCIATES INC (billing NPI 1790875656) in the available physician profile data.

Does Shabana J. Dewani, MD have Open Payments data?

Shabana J. Dewani, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.